Adjuvant pembrolizumab for patients with resected, high-risk stage III melanoma reduces the risk for recurrences and distant metastases Adjuvant pembrolizumab for patients with resected, high-risk stage III melanoma reduces the risk for recurrences and distant metastases Pharma News Read more
